Maxim Group set a $15.00 price target on Anavex Life Sciences Corp. (NASDAQ:AVXL) in a research report report published on Monday. The firm currently has a buy rating on the biotechnology company’s stock.

Other research analysts also recently issued research reports about the company. Noble Financial restated a buy rating on shares of Anavex Life Sciences Corp. in a report on Sunday, May 14th. Zacks Investment Research upgraded Anavex Life Sciences Corp. from a hold rating to a buy rating and set a $7.00 price target on the stock in a report on Wednesday, April 12th. Finally, ValuEngine upgraded Anavex Life Sciences Corp. from a sell rating to a hold rating in a report on Thursday, August 3rd. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Anavex Life Sciences Corp. presently has a consensus rating of Buy and an average price target of $11.94.

Shares of Anavex Life Sciences Corp. (AVXL) traded down 3.5660% during midday trading on Monday, hitting $3.7995. The company had a trading volume of 347,195 shares. Anavex Life Sciences Corp. has a 52 week low of $2.43 and a 52 week high of $6.64. The firm’s 50 day moving average is $5.12 and its 200 day moving average is $5.47. The company’s market capitalization is $157.21 million.

Anavex Life Sciences Corp. (NASDAQ:AVXL) last announced its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.09). Equities research analysts anticipate that Anavex Life Sciences Corp. will post ($0.37) EPS for the current year.

TRADEMARK VIOLATION NOTICE: This piece of content was posted by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2017/08/08/maxim-group-analysts-give-anavex-life-sciences-corp-nasdaqavxl-a-15-00-price-target.html.

Hedge funds and other institutional investors have recently bought and sold shares of the company. State Street Corp increased its position in Anavex Life Sciences Corp. by 27.2% in the fourth quarter. State Street Corp now owns 391,065 shares of the biotechnology company’s stock worth $1,549,000 after buying an additional 83,716 shares during the period. Highbridge Capital Management LLC purchased a new position in Anavex Life Sciences Corp. during the fourth quarter worth $151,000. Edge Wealth Management LLC purchased a new position in Anavex Life Sciences Corp. during the first quarter worth $230,000. Bank of New York Mellon Corp increased its position in Anavex Life Sciences Corp. by 5.5% in the first quarter. Bank of New York Mellon Corp now owns 111,880 shares of the biotechnology company’s stock worth $642,000 after buying an additional 5,826 shares during the period. Finally, JPMorgan Chase & Co. purchased a new position in Anavex Life Sciences Corp. during the first quarter worth $105,000. Hedge funds and other institutional investors own 22.88% of the company’s stock.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.

Receive News & Ratings for Anavex Life Sciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences Corp. and related companies with MarketBeat.com's FREE daily email newsletter.